Discounted Cash Flow
Syndax Pharmaceuticals Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $1.2m | $-44.5m | $-35.4m | -3645.2% | $-3.22 |
| 2017 | $2.1m (72.8%) | $-60.8m (-36.7%) | $-47.5m (-34.0%) | -2884.3% (20.9%) | $-2.90 (9.9%) |
| 2018 | $1.5m (-28.0%) | $-74.0m (-21.6%) | $-68.7m (-44.8%) | -4875.5% (-69.0%) | $-2.92 (-0.7%) |
| 2019 | $1.5m (0.0%) | $-56.0m (24.2%) | $-50.6m (26.3%) | -3694.6% (24.2%) | $-1.84 (37.0%) |
| 2020 | $1.5m (0.0%) | $-73.2m (-30.5%) | $-71.3m (-40.8%) | -4822.5% (-30.5%) | $-1.87 (-1.6%) |
| 2021 | $139.7m (9109.6%) | $24.9m (134.1%) | $29.0m (140.7%) | 17.8% (100.4%) | $0.48 (125.7%) |
| 2022 | $0 (-100.0%) | $-149.3m (-699.1%) | $-133.7m (-560.9%) | — | $-2.46 (-612.5%) |
| 2023 | $0 | $-209.4m (-40.2%) | $-160.6m (-20.1%) | — | $-2.98 (-21.1%) |
| 2024 | $23.7m | $-318.8m (-52.3%) | $-274.9m (-71.2%) | -1346.1% | $-3.72 (-24.8%) |
| 2025 | $172.4m (627.8%) | $-285.4m (10.5%) | $-323.2m (-17.6%) | -165.6% (87.7%) | $-3.29 (11.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.